Novavax Selects AGC Biologics To Manufacture Adjuvant Matrix-M ™ For New COVID-19 Vaccine
AGC Biologic s , a global biopharmaceutical contract development and manufacturing (CDMO) organization, has announced that it will partner with Novavax , Inc. (NASDAQ: NVAX), a late-phase biopharmaceutical company developing next-generation vaccines for serious infectious diseases, in large-scale production of GMP for all vital components of Novavax's coronavirus vaccine candidate, NVX-CoV2373. AGC Biologics will manufacture Matrix-M ™, an adjuvant component for the vaccine, in order to improve the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 is a stable prefusion protein created using Novavax's proprietary nanoparticle technology. AGC Biologics will streamline process development for Matrix-M production growth, greatly increasing Novavax's ability to deploy doses in 2020 and 2021.
"We are growing rapidly to successfully deploy a vital vaccine component for Novavax," explained AGC Biologics CEO Patricio Massera . "The urgency of aid to help produce a vaccine in the fight against COVID-19 could not be more important."
"The mission of AGC Biologics is to work side-by-side with our partners to create products that save and prolong life," said Mark Womack , Biological Manager, AGC Biologics. "Partnering with Novavax to manufacture this vaccine component is an incredible opportunity to make a profound positive difference."
"We have been impressed by the level of collaboration and commitment shown by AGC Biologics," said Timothy J. Hahn , senior vice president of processes and technology at Novavax. "It is an important strategic partner in expanding our adjuvant supply chain for NVX-CoV2373 and for other vaccines developed by Novavax, including our seasonal recombinant influenza vaccine, NanoFlu ™."